Ken Griffin Novavax Inc Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novavax Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 829,244 shares of NVAX stock, worth $6.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

829,244

Previous 511,600 62.09%

Holding current value

$6.96 Million

Previous $3.28 Million 59.32%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$5.43 - $7.74 $4.55 Million - $6.49 Million	-838,473 Reduced 50.28%	829,244 $5.22 Million
Q1 2025 May 15, 2025	BUY	$6.41 - $10.82 $5.22 Million - $8.81 Million	814,226 Added 95.4%	1,667,717 $10.7 Million
Q4 2024 Feb 14, 2025	BUY	$7.22 - $14.68 $2.09 Million - $4.25 Million	289,446 Added 51.32%	853,491 $6.86 Million
Q3 2024 Nov 14, 2024	SELL	$10.71 - $17.11 $630,979 - $1.01 Million	-58,915 Reduced 9.46%	564,045 $7.12 Million
Q2 2024 Aug 14, 2024	BUY	$3.89 - $20.97 $1.29 Million - $6.97 Million	332,309 Added 114.33%	622,960 $7.89 Million
Q1 2024 May 15, 2024	BUY	$3.76 - $6.02 $1.09 Million - $1.75 Million	290,651 New	290,651 $1.39 Million
Q3 2023 Nov 14, 2023	SELL	$6.81 - $9.74 $505,404 - $722,854	-74,215 Reduced 87.12%	10,970 $79,000
Q2 2023 Aug 14, 2023	BUY	$6.67 - $9.52 $560,886 - $800,546	84,091 Added 7686.56%	85,185 $632,000
Q1 2023 May 15, 2023	SELL	$5.76 - $12.48 $2.12 Million - $4.59 Million	-368,053 Reduced 99.7%	1,094 $7,000
Q4 2022 Feb 14, 2023	SELL	$8.86 - $25.04 $5.95 Million - $16.8 Million	-671,146 Reduced 64.52%	369,147 $3.79 Million
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $6.39 Million - $26.7 Million	351,134 Added 50.95%	1,040,293 $18.9 Million
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $4.5 Million - $9.34 Million	124,043 Added 21.95%	689,159 $35.4 Million
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $33.8 Million - $69.3 Million	484,628 Added 602.11%	565,116 $41.6 Million
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $15 Million - $24.2 Million	-111,244 Reduced 58.02%	80,488 $11.5 Million
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $87.4 Million - $133 Million	-491,736 Reduced 71.95%	191,732 $39.7 Million
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $39.5 Million - $84.2 Million	326,732 Added 91.59%	683,468 $145 Million
Q1 2021 May 17, 2021	SELL	$112.98 - $319.93 $40.3 Million - $114 Million	-356,459 Reduced 49.98%	356,736 $64.7 Million
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $30.7 Million - $54.3 Million	389,536 Added 120.35%	713,195 $79.5 Million
Q3 2020 Nov 16, 2020	SELL	$79.44 - $178.51 $36.3 Million - $81.5 Million	-456,749 Reduced 58.53%	323,659 $35.1 Million
Q2 2020 Aug 14, 2020	BUY	$13.86 - $83.61 $10.4 Million - $62.9 Million	751,875 Added 2635.11%	780,408 $65 Million
Q1 2020 May 15, 2020	BUY	$3.93 - $16.0 $16,576 - $67,488	4,218 Added 17.35%	28,533 $387,000
Q3 2019 Nov 14, 2019	BUY	$4.02 - $7.84 $97,746 - $190,629	24,315 New	24,315 $122,000

Others Institutions Holding NVAX

# of Institutions

316

Shares Held

94.7M

Call Options Held

6.11M

Put Options Held

10.5M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $656M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account